|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Nonalcoholic fatty liver disease is a novel predictor of cardiovascular disease显示文摘AIM:To clarify whether nonalcoholic fatty liver disease(NAFLD)increases the risk of cardiovascular disease.METHODS:We carried out a prospective observational study with a total of 1637 apparently healthy Japanese men and women who were recruited from a health check-up program.NAFLD was diagnosed by abdominal ultrasonography.The metabolic syndrome(MS)was defined according to the modified National Cholesterol Education Program(NCEP)ATP Ⅲ criteria.Five years after the baseline evaluations,the incidence of cardiovascular disease was assessed by a self-administered questionnaire.RESULTS:Among 1221 participants available for outcome analyses,the incidence of cardiovascular disease was higher in 231 subjects with NAFLD at baseline(5 coronary heart disease,6 ischemic stroke,and 1 cerebral hemorrhage)than 990 subjects without NAFLD(3 coronary heart disease,6 ischemic stroke,and 1 cerebral hemorrhage).Multivariate analyses indicated that NAFLD was a predictor of cardiovascular disease independent of conventional risk factors(odds ratio 4.12,95% CI,1.58 to 10.75,P = 0.004).MS was alsoindependently associated with cardiovascular events.But simultaneous inclusion of NAFLD and MS in a multivariate model revealed that NAFLD but not MS retained a statistically significant correlation with cardiovascular disease.CONCLUSION:Although both of them were predictors of cardiovascular disease,NAFLD but not MS retained a statistically significant correlation with cardiovascular disease in a multivariate model.NAFLD is a strong predictor of cardiovascular disease and may play a central role in the cardiovascular risk of MS. | Masahide Hamaguchi Takao Kojima Noriyuki Takeda Chisato Nagata Jun Takeda Hiroshi Sarui Yutaka Kawahito Naohisa Yoshida Atsushi Suetsugu Takahiro Kato Junichi Okuda Kazunori Ida Toshikazu Yoshikawa | 2007 | World Journal of Gastroenterology2007，13，10： | 55 |
| 2 | Current issues and future perspectives of gastric cancer screening显示文摘Gastric cancer remains the second leading cause of cancer death worldwide. About half of the incidence of gastric cancer is observed in East Asian countries,which show a higher mortality than other countries. The effectiveness of 3 new gastric cancer screening techniques,namely,upper gastrointestinal endoscopy,serological testing,and 'screen and treat' method were extensively reviewed. Moreover,the phases of development for cancer screening were analyzed on the basis of the biomarker development road map. Several observational studies have reported the effectiveness of endoscopic screening in reducing mortality from gastric cancer. On the other hand,serologic testing has mainly been used for targeting the high-risk group for gastric cancer. To date,the effectiveness of new techniques for gastric cancer screening has remained limited. However,endoscopic screening is presently in the last trial phase of development before their introduction to population-based screening.To effectively introduce new techniques for gastric cancer screening in a community,incidence and mortality reduction from gastric cancer must be initially and thoroughly evaluated by conducting reliable studies.In addition to effectiveness evaluation,the balance of benefits and harms must be carefully assessed before introducing these new techniques for population-based screening. | Chisato Hamashima | 2014 | World Journal of Gastroenterology2014，20，38： | 46 |
| 3 | Impact of endoscopic screening on mortality reduction from gastric cancer显示文摘AIM:To investigate mortality reduction from gastric cancer based on the results of endoscopic screening.METHODS:The study population consisted of participants of gastric cancer screening by endoscopy,regular radiography,and photofluorography at Niigata city in 2005.The observed numbers of cumulative deaths from gastric cancers and other cancers were accumulated by linkage with the Niigata Prefectural Cancer Registry.The standardized mortality ratio(SMR)of gastric cancer and other cancer deaths in each screening group was calculated by applying the mortality rate of the reference population.RESULTS:Based on the results calculated from the mortality rate of the population of Niigata city,the SMRs of gastric cancer death were 0.43(95%CI:0.30-0.57)for the endoscopic screening group,0.68(95%CI:0.55-0.79)for the regular radiographic screening group,and 0.85(95%CI:0.71-0.94)for the photofluorography screening group.The mortality reduction from gastric cancer was higher in the endoscopic screening group than in the regular radiographic screening group despite the nearly equal mortality rates of all cancers except gastric cancer.CONCLUSION:The 57%mortality reduction from gastric cancer might indicate the effectiveness of endoscopic screening for gastric cancer.Further studies and prudent interpretation of results are needed. | Chisato Hamashima Kazuei Ogoshi Rintarou Narisawa Tomoki Kishi Toshiyuki Kato Kazutaka Fujita Masatoshi Sano Satoshi Tsukioka | 2015 | World Journal of Gastroenterology2015，21，8： | 16 |
| 4 | Identification of individuals with non-alcoholic fatty liver disease by the diagnostic criteria for the metabolic syndrome显示文摘AIM:To clarify the efficiency of the criterion of metabolic syndrome to detecting non-alcoholic fatty liver disease(NAFLD).METHODS:Authors performed a cross-sectional study involving participants of a medical health checkup program including abdominal ultrasonography.This study involved 11 714 apparently healthy Japanese men and women,18 to 83 years of age.NAFLD was defined by abdominal ultrasonography without an alcohol intake of more than 20 g/d,known liver disease,or current use of medication.The revised criteria of the National Cholesterol Education Program Adult Treatment PanelⅢ were used to characterize the metabolic syndrome.RESULTS:NAFLD was detected in 32.2%(95%CI:31.0%-33.5%)of men(n=1874 of 5811)and in 8.7%(95%CI:8.0%-9.5%)of women(n=514 of 5903).Among obese people,the prevalence of NAFLD was as high as 67.3%(95%CI:64.8%-69.7%)in men and 45.8%(95%CI:41.7%-50.0%)in women.Although NAFLD was thought of as being the liver phenotype of metabolic syndrome,the prevalence of the metabolic syndrome among subjects with NAFLD was low both in men and women.66.8%of men and 70.4%of women with NAFLD were not diagnosed with the metabolic syndrome.48.2%of men with NAFLD and 49.8%of women with NAFLD weren't overweight[body mass index(BMI)≥25 kg/m2].In the same way,68.6%of men with NAFLD and 37.9%of women with NAFLD weren't satisfied with abdominal classification(≥90 cm for men and≥80 cm for women).Next,authors defined it as positive at screening for NAFLD when participants satisfied at least one criterion of metabolic syndrome.The sensitivity of the definition'at least 1 criterion'was as good as 84.8%in men and 86.6%in women.Separating subjects by BMI,the sensitivity was higher in obese men and women than in non-obese men and women(92.3%vs 76.8%in men,96.1%vs 77.0%in women,respectively).CONCLUSION:Authors could determine NAFLD effectively in epidemiological study by modifying the usage of the criteria for metabolic syndrome. | Masahide Hamaguchi Noriyuki Takeda Takao Kojima Akihiro Ohbora Takahiro Kato Hiroshi Sarui Michiaki Fukui Chisato Nagata Jun Takeda | 2012 | World Journal of Gastroenterology2012，18，13： | 13 |
| 5 | Benefits and harms of endoscopic screening for gastric cancer显示文摘Gastric cancer has remained a serious burden worldwide, particularly in East Asian countries. However, nationwide prevention and screening programs for gastric cancer have not yet been established in most countries except in South Korea and Japan. Although evidence regarding the effectiveness of endoscopic screening for gastric cancer has been increasingly accumulated, such evidence remains weak because it is based on results from studies other than randomized controlled trials. Specifically, evidence was mostly based on the results of cohort and case-control studies mainly conducted in South Korea and Japan. However, the consistent positive results from these studies suggest promising evidence of mortality reduction from gastric cancer by endoscopic screening. The major harms of endoscopic screening include infection, adverse effects, false-positive results, and overdiagnosis. Despite the possible harms of endoscopic screening, information regarding these harms remains insufficient. To provide appropriate cancer screening, a balance of benefits and harms should always be considered when cancer screening is introduced as a public policy. Quality assurance is very important for the implementation of cancer screening to provide high-quality and safe screening and minimize harms. Endoscopic screening for gastric cancer has shown promising results, and thus deserves further evaluation to reliably establish its effectiveness and optimal use. | Chisato Hamashima | 2016 | World Journal of Gastroenterology2016，22，28： | 10 |
| 6 | Overdiagnosis of gastric cancer by endoscopic screening显示文摘Gastric cancer screening using endoscopy has recently spread in Eastern Asian countries showing increasing evidence of its effectiveness. However, despite the benefits of endoscopic screening for gastric cancer, its major harms include infection, complications, falsenegative results, false-positive results, and overdiagnosis. The most serious harm of endoscopic screening is overdiagnosis and this can occur in any cancer screening programs. Overdiagnosis is defined as the detection of cancers that would never have been found if there is no cancer screening. Overdiagnosis has been estimated from randomized controlled trials, observational studies, and modeling. It can be calculated on the basis of a comparison of the incidence of cancer between screened and unscreened individuals after the follow-up. Although the estimation method for overdiagnosis has not yet been standardized, estimation of overdiagnosis is needed in endoscopic screening for gastric cancer. To minimize overdiagnosis, the target age group and screening interval should be appropriately defined. Moreover, the balance of benefits and harms must be carefully considered to effectively introduce endoscopic screening in communities. Further research regarding overdiagnosis is warranted when evaluating the effectiveness of endoscopic screening. | Chisato Hamashima | 2017 | World Journal of Gastrointestinal Endoscopy2017，9，2： | 4 |
| 7 | Clinical usefulness of ursodeoxycholic acid for Japanese patients with autoimmune hepatitis显示文摘AIM To evaluate the therapeutic effects of ursodeoxycholic acid(UDCA) on autoimmune hepatitis(AIH).METHODS A total 136 patients who were diagnosed with AIH were included in our study. All of the patients underwent a liver biopsy, and had at least a probable diagnosis on the basis of either the revised scoring system or the simplified scores. Initial treatment included UDCA monotherapy(Group U, n = 48) and prednisolone(PSL) monotherapy(Group P, n = 88). Group U was further classified into two subgroups according to the effect of UDCA: Patients who had achieved remission induction with UDCA monotherapy and showed no sign of relapse(Subgroup U1, n = 34) and patients who additionally received PSL during follow-up(Subgroup U2, n = 14). We compared the clinical and histological findings between each groups, and investigated factorscontributing to the response to UDCA monotherapy.RESULTS In Group U, 34 patients(71%) achieved and maintained remission over 49(range: 8-90) mo(Subgroup U1) and 14 patients(29%) additionally received PSL(Subgroup U2) during follow-up. Two patients in Subgroup U2 achieved remission induction once but additionally required PSL administration because of relapse(15 and 35 mo after the start of treatment). The remaining 12 patients in Subgroup U2 failed to achieve remission induction during follow-up, and PSL was added during 7(range: 2-18) mo. Compared with Subgroup U2, Subgroup U1 had significantly lower alanine aminotransferase(ALT) levels at onset(124 IU/L vs 262 IU/L, P = 0.023) and a significantly higher proportion of patients with mild inflammation(A1) on histological examination(70.6% vs 35.7%, P = 0.025). When multivariate analysis was performed to identify factors contributing to the response to UDCA monotherapy, only a serum ALT level of 200 IU/L or lower was found to be associated with a significant difference(P = 0.013).CONCLUSION To prevent adverse events related to corticosteroids, UDCA monotherapy for AIH needs to be considered in patients with a serum ALT level of 200 IU/L or lower. | Yuichi Torisu Masanori Nakano Keiko Takano Ryo Nakagawa Chisato Saeki Atsushi Hokari Tomohisa Ishikawa Masayuki Saruta Mikio Zeniya | 2017 | World Journal of Hepatology2017，9，1： | 3 |
| 8 | Effects of denosumab treatment in chronic liver disease patients with osteoporosis显示文摘BACKGROUND Effective treatment of osteoporosis is essential for improving morbidity and health-related quality of life in chronic liver disease(CLD)patients.Denosumab has been shown to increase bone mineral density(BMD)and decrease the risk of osteoporotic fracture in the general population.However,there are few reports evaluating the efficacy of denosumab in CLD patients.AIM To investigated the effects and safety of denosumab in CLD patients with osteoporosis.METHODS Sixty CLD patients with osteoporosis were subcutaneously administered denosumab once every 6 mo.The study period for evaluating efficacy and safety was 12 mo.Changes from baseline in BMD at the lumbar spine,femoral neck,and total hip were evaluated at 12 mo of denosumab treatment.Bone turnover and quality were assessed by measuring serum tartrate-resistant acid phosphatase-5b(bone resorption marker),serum total procollagen type I N-terminal propeptide(bone formation maker),and plasma pentosidine(bone quality marker).RESULTS Among the 405 CLD patients,138(34.1%)patients were diagnosed with osteoporosis;among these,78 patients met the exclusion criteria and thus 60 patients were finally included in the present study.The median percentage changes from baseline to 12 mo of denosumab treatment in BMD at the lumbar spine,femoral neck,and total hip were+4.44%,+3.71%,and+4.03%,respectively.Denosumab significantly improved BMD,regardless of sex,patient age,and presence of liver cirrhosis.Serum tartrate-resistant acid phosphatase-5b and procollagen type I N-terminal propeptide levels constantly and significantly declined after denosumab treatment(P<0.001).Plasma pentosidine levels were also significantly lower at 12 mo of treatment(P=0.010).No patients experienced fractures and moderate-to-severe adverse events,except for transient hypocalcemia.CONCLUSION Denosumab treatment was safe and increased BMD,suppressed bone turnover,and improved bone quality marker levels in CLD patients with osteoporosis,irrespective of differences in baseline characteristics. | Chisato Saeki Mitsuru Saito Tsunekazu Oikawa Masanori Nakano Yuichi Torisu Masayuki Saruta Akihito Tsubota | 2020 | World Journal of Gastroenterology2020，26，33： | 3 |
| 9 | Percoll fractionation of adult mouse spermatogonia improvesgerm cell transplantation显示文摘Aim: To isolate and transplant germ cells from adult mouse testes for transplantation. Methods: In order to distinguish transplanted cells from endogenous cells of recipients, donor transgenic mice expressing green fluorescent protein (GFP) were used. Germ cells were collected from the donors at 10-12 weeks of age and spermatogonia were concentrated by percoll fractionation and transplanted into recipient seminiferous tubules that had been previously treated with busulfan at 5 weeks of age to remove the endogenous spermatogenic cells. Results: Twenty weeks after the transplantation, a wide spread GFP signal was observed in the recipient seminiferous tubules. The presence of spermatogenesis and spermatozoa was confirmed in sections of 12 out of 14 testes transplanted (86%).However, when germ cells were transplanted without concentration the success rate was zero (0/9). Conclusion:Germ cells from adult mouse testes can be successfully transplanted into recipient seminiferous tubules if the cell population is rich in spermatogonia and the percoll fractionation is useful in obtaining such a cell population. | Kyu-Bom Koh Masatoshi Komiyama Yoshiro Toyama Tetsuya Adachi Chisato Mori | 2004 | Asian Journal of Andrology2004，6，2： | 3 |
| 10 | Mouse models for investigating the underlying mechanisms of nonalcoholic steatohepatitis-derived hepatocellular carcinoma显示文摘As the incidence of hepatocellular carcinoma(HCC) caused by infection with the hepatotropic viruses hepatitis B and hepatitis C decreases, greater attention has become focused on HCC caused by nonalcoholic steatohepatitis(NASH), an advanced form of nonalcoholic fatty liver disease which has shown increasing prevalence in correspondence with the overall increase in metabolic syndrome over the recent decades. Several clinical population studies have shown a positive relationship between NASH and HCC, while also providing initial insights into the underlying mechanisms of HCC development from NASH. Research into the pathological progression of NASH to HCC has advanced by use of several beneficial rodent models. In this review, we summarize the established mouse models for preclinical research of NASH-associated HCC and discuss the underlying hepatic mechanisms of NASH-related tumorigenesis identified to date that could lead to new targets for treatment and prevention. | Kazuki Takakura Tsunekazu Oikawa Yoichi Tomita Yusuke Mizuno Masanori Nakano Chisato Saeki Yuichi Torisu Masayuki Saruta | 2018 | World Journal of Gastroenterology2018，24，18： | 2 |
| 11 | Preoperative Ultrasonographic Examination for Lymph Node Metastasis: Usefulness when Designing Lymph Node Dissection for Papillary Microcarcinoma of the Thyroid显示文摘 | Yasuhiro Ito M.D. Ph.D. Chisato Tomoda M.D. Takashi Uruno M.D. Yuuki Takamura M.D. Akihiro Miya M.D. Kaoru Kobayashi M.D. Fumio Matsuzuka M.D. Kanji Kuma M.D. Akira Miyauchi M.D | 2004 | World Journal of Surgery2004，，5： | 1 |
| 12 | Cost-effectiveness analysis of prostate cancer screening显示文摘 | Chisato Hamashima Katsumi Yoshida | 2000 | Environmental Health and Preventive Medicine2000，，3： | 1 |
| 13 | Relation of risk factors with response to carvedilol in heart failure with preserved ejection fraction – A report from the Japanese Diastolic Heart Failure Study (J-DHF)显示文摘 | Kazuhiro Yamamoto Hideki Origasa Yasushi Suzuki Toshiaki Takahashi Tsuyoshi Shinozaki Tomoyuki Watanabe Yasushi Sakata Chisato Izumi Kayano Taira Masatsugu Hori | 2013 | Journal of Cardiology2013，，： | 1 |
| 14 | Prevention of aortic calcification by etidronate in the renal failure rat model显示文摘 | Kazuhiro Tamura Yusuke Suzuki Mayumi Matsushita Hiroyuki Fujii Chisato Miyaura Sumio Aizawa Hiroshi Kogo | 2006 | European Journal of Pharmacology2006，，1： | 1 |
| 15 | Reactive oxygen species, ap- optosis, and mitoehordrial dys显示文摘 | Teru K Chisato F Tatsuya Y | 2015 | Bio Med Res Int2015，，： | 1 |
| 16 | Excellent Prognosis of Patients with Solitary T1N0M0 Papillary Thyroid Carcinoma Who Underwent Thyroidectomy and Elective Lymph Node Dissection Without Radioiodine Therapy显示文摘 | Yasuhiro Ito Hiroo Masuoka Mitsuhiro Fukushima Hiroyuki Inoue Minoru Kihara Chisato Tomoda Takuya Higashiyama Yuuki Takamura Kaoru Kobayashi Akihiro Miya Akira Miyauchi | 2010 | World Journal of Surgery2010，，6： | 1 |
| 17 | Prgparation of SnO2 monolithic gel by sol-gel method显示文摘 | Haruhisa S Chisato K Atsushi N | 2000 | Sol-Gel Sci Technol2000，，9： | 1 |
| 18 | The design and optimization of a series of 2-( pyridin-2-yl)-1H-benzimidazole com- pounds as allosteric glucokinase activators 显示文摘 | KEIJI T NORIAKI H CHISATO N | 2009 | Bioorgan Med Chem2009，17，19： | 1 |
| 19 | miR-196b targets c- myc and Bcl-2 expression, inhibits proliferation and induces apoptosis in endometriotic stromal cells 显示文摘 | ABE W NASU K CHISATO N | 2013 | Hum Reprod2013，28，： | 1 |
| 20 | Accumulation of cadmium and zinc in Evodiopanax innovans显示文摘 | Chisato Takenaka Motoharu Kobayashi Shotaro Kanaya | 2009 | Environ Geochem Health2009，31，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员